KR940003951A

KR940003951A - Piperidino-3, 4-dihydrocarbocytyl compound

Info

Publication number: KR940003951A
Application number: KR1019930015405A
Authority: KR
Inventors: 아라오 우지이에; 히로무 하라다; 아키라 이요베; 마사히코 우치다; 고지 가마타
Original assignee: 간자와 무츠오; 깃세이 야쿠힝 고교 가부시키가이샤
Priority date: 1992-08-11
Filing date: 1993-08-09
Publication date: 1994-03-14

Abstract

본 발명은 일반식 :The present invention is a general formula:

(여기서, R¹은 수산기 또는 탄소원자수 2 내지 11의 아실옥시기를 나타내며, R²와 R³중의 하나는 니트로기, 시아노기, 탄소원자수 2 내지 7의 알콕시카르보닐기, 탄소원자수 1 내지 4의 알킬기, 탄소원자수 1 내지 3의 할로알킬기, 또는 할로겐원자를 나타내고, 다른 하나는 수소원자를 나타낸다)으로 표시되는 것을 특징으로 하는 피페리디노-3, 4-디히로카르보시티릴 화합물 및 약학적으로 허용가능한 그 염에 관한 것으로, 이는 혈소판 응집방지의 활동성을 나타내어 뇌빈혈증 및 동맥빈혈증의 예방 또는 처치용 치료제로서 유효하다.(Wherein R ¹ represents a hydroxyl group or an acyloxy group having 2 to 11 carbon atoms, one of R ² and R ³ represents a nitro group, a cyano group, an alkoxycarbonyl group having 2 to 7 carbon atoms, an alkyl group having 1 to 4 carbon atoms, A piperidino-3, 4-dihydrocarbocytyl compound and a pharmaceutically acceptable compound, characterized by a haloalkyl group having 1 to 3 carbon atoms, or a halogen atom, and another hydrogen atom). It relates to salts, which exhibit the activity of platelet aggregation prevention and are effective as a therapeutic agent for the prevention or treatment of encephalopathy and arterial anemia.

Description

Piperidino-3, 4-dihydrocarbocytyl compound

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims

General formula:

(Wherein R ¹ represents a hydroxyl group or an acyloxy group having 2 to 11 carbon atoms, one of R ² and R ³ represents a nitro group, a cyano group, an alkoxycarbonyl group having 2 to 7 carbon atoms, an alkyl group having 1 to 4 carbon atoms, Piperidino-3, 4-dihydrocarbocytyl compound, and a pharmaceutically acceptable, characterized by a haloalkyl group having 1 to 3 carbon atoms, or a halogen atom and the other hydrogen atom). Its salts possible.

The method of claim 1, wherein the general formula:

Wherein one of R ² and R ³ represents a nitro group, a cyano group, an alkoxycarbonyl group having 2 to 7 carbon atoms, an alkyl group having 1 to 4 carbon atoms, a haloalkyl group having 1 to 3 carbon atoms, or a halogen atom, and Piperidino-3, 4-dihydrocarbocytyl compound and a pharmaceutically acceptable salt thereof, wherein one represents a hydrogen atom.

The method according to claim 2, wherein the general formula:

Wherein the compound is represented by R'nitro group, cyano group, alkoxycarbonyl group having 2 to 7 carbon atoms, alkyl group having 1 to 4 carbon atoms, haloalkyl group having 1 to 3 carbon atoms, or halogen atom. Ferridino-3, 4-dihydrocarbocytyl compound and pharmaceutically acceptable salts thereof.

The method of claim 3, wherein the general formula:

Wherein R ^{3 "} is a cyano group, a haloalkyl group having 1 to 3 carbon atoms, or a halogen atom), and a piperidino-3, 4-dihydrocarbocytyl compound, and a pharmaceutically acceptable Its salts possible.

The method according to claim 4, wherein the general formula:

7-fluoro-6- (4-hydroxypiperidino) -3, 4-dihydrocarbostyryl compound, and a pharmaceutically acceptable salt thereof, characterized by being represented by:

※ Note: The disclosure is based on the initial application.